These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24790218)

  • 41. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
    Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
    J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
    MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
    Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
    Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
    Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
    J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.
    Bariani GM; Carvalheira JB; Riechelmann RP
    Onkologie; 2013; 36(9):502-4. PubMed ID: 24051927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
    Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
    Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in biodistribution on
    Cherk MH; Kong G; Hicks RJ; Hofman MS
    Cancer Imaging; 2018 Jan; 18(1):3. PubMed ID: 29361984
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
    Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
    [No Abstract]   [Full Text] [Related]  

  • 56. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
    Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
    Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroendocrine tumors: treatment updates.
    Khagi S; Saif MW
    JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Kok IC; Hooiveld JS; van de Donk PP; Giesen D; van der Veen EL; Lub-de Hooge MN; Brouwers AH; Hiltermann TJN; van der Wekken AJ; Hijmering-Kappelle LBM; Timens W; Elias SG; Hospers GAP; Groen HJM; Uyterlinde W; van der Hiel B; Haanen JB; de Groot DJA; Jalving M; de Vries EGE
    Ann Oncol; 2022 Jan; 33(1):80-88. PubMed ID: 34736925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.